CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

My Organizations' Clinical Trials

Showing 50 of 124 entries

View as:

Development and Application of Molecular Evaluation Instrument for Lung Cancer Diagnosis and Treatment

Phase: N/A Priority: Normal

NCT ID: NCT06086587 Org: User:

Start: 11/07/23 End: 10/31/25 Due: 10/31/26

Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm

Phase: N/A Priority: Normal

NCT ID: NCT04937283 Org: User:

Start: 10/01/19 End: 12/30/28 Due: 12/30/29

Study of Subcutaneous Injection of Low-dose rhGM-CSF +/- WLL in PAP.

Phase: N/A Priority: Normal

NCT ID: NCT01983657 Org: User:

Start: 01/31/12 End: 10/31/14 Due: 10/31/15

A Study on the Efficacy of Atezolizumab Combined with Chemotherapy

Phase: N/A Priority: Normal

NCT ID: NCT06780826 Org: User:

Start: 08/28/24 End: 09/30/25 Due: 09/30/26

Construction and Evaluation of the Liquid Biopsy-based Early Diagnostic Model for Lung Cancer

Phase: N/A Priority: Normal

NCT ID: NCT04156360 Org: User:

Start: 11/01/19 End: 06/01/21 Due: 06/01/22

Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung Disease

Phase: N/A Priority: Normal

NCT ID: NCT05824988 Org: User:

Start: 04/14/23 End: 10/31/26 Due: 10/31/27

Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%

Phase: N/A Priority: Normal

NCT ID: NCT03351842 Org: User:

Start: 09/01/17 End: 09/01/24 Due: 09/01/25

Comparison of Single Port and Two Ports Robotic Assisted Thoracic Surgery for Thymectomy

Phase: N/A Priority: Normal

NCT ID: NCT05262582 Org: User:

Start: 05/10/22 End: 01/01/25 Due: 01/01/26

Clinical Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis

Phase: N/A Priority: Normal

NCT ID: NCT02136992 Org: User:

Start: 12/31/11 End: 12/31/13 Due: 12/31/14

CX3CR1+T Cell Predict Immunotherapy Efficacy

Phase: N/A Priority: Normal

NCT ID: NCT06054152 Org: User:

Start: 04/10/23 End: 06/20/25 Due: 06/20/26

Multicenter Observational Study of Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Rare Driver Gene Mutation

Phase: N/A Priority: Normal

NCT ID: NCT04137718 Org: User:

Start: 10/25/19 End: 10/20/24 Due: 10/20/25

Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer

Phase: N/A Priority: Normal

NCT ID: NCT04702009 Org: User:

Start: 01/20/21 End: 01/20/26 Due: 01/20/27

Therapy of Bronchoalveolar Lavage and Local Amikacin Injection in Patients With Acute Exacerbation of Bronchiectasis

Phase: N/A Priority: Normal

NCT ID: NCT02509091 Org: User:

Start: 12/31/14 End: 06/30/19 Due: 06/30/20

The C-BRIDGE Study: China Bronchiectasis Research Involving Databases, Genomics, and Endotyping

Phase: N/A Priority: Normal

NCT ID: NCT06900062 Org: User:

Start: 04/06/25 End: 01/31/29 Due: 01/31/30

Deep Learning Signature for Predicting Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung Cancer

Phase: N/A Priority: Normal

NCT ID: NCT05925751 Org: User:

Start: 05/01/23 End: 10/31/23 Due: 10/31/24

a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung Cancer

Phase: N/A Priority: Normal

NCT ID: NCT04790539 Org: User:

Start: 04/01/21 End: 12/31/22 Due: 12/31/23

A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB

Phase: N/A Priority: Normal

NCT ID: NCT05493267 Org: User:

Start: 08/03/22 End: 08/03/27 Due: 08/03/28

Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma

Phase: N/A Priority: Normal

NCT ID: NCT04713761 Org: User:

Start: 02/01/21 End: 05/31/25 Due: 05/31/26

Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients

Phase: N/A Priority: Normal

NCT ID: NCT06987734 Org: User:

Start: 06/19/25 End: 08/31/28 Due: 08/31/29

Updated Severity and Prognosis Score of Pulmonary Alveolar Proteinosis

Phase: N/A Priority: Normal

NCT ID: NCT04516577 Org: User:

Start: 01/01/20 End: 12/31/21 Due: 12/31/22

A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC

Phase: N/A Priority: Normal

NCT ID: NCT06585644 Org: User:

Start: 10/01/24 End: 06/01/30 Due: 06/01/31

Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial

Phase: N/A Priority: Normal

NCT ID: NCT06282536 Org: User:

Start: 03/31/24 End: 12/31/29 Due: 12/31/30

Transthoracic Needle Biopsy Using 3D Printed Navigational Template: A Phase I Feasibility Trial

Phase: N/A Priority: Normal

NCT ID: NCT03325907 Org: User:

Start: 06/01/20 End: 09/03/20 Due: 09/03/21

Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study

Phase: N/A Priority: Normal

NCT ID: NCT04762030 Org: User:

Start: 02/08/21 End: 12/30/25 Due: 12/30/26

Clinical Study of New Intensive Treatment Regimen for Severe Nontuberculous Mycobacterial Pulmonary Disease

Phase: N/A Priority: Normal

NCT ID: NCT05494957 Org: User:

Start: 08/05/22 End: 08/05/25 Due: 08/05/26

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
Development and Application of Molecular Evaluation Instrument for Lung Cancer Diagnosis and Treatment	NCT06086587	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2023-11-07	2025-10-31	2026-10-31	-	-	2025-07-14
Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm	NCT04937283	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2019-10-01	2028-12-30	2029-12-30	-	-	2025-07-14
Study of Subcutaneous Injection of Low-dose rhGM-CSF +/- WLL in PAP.	NCT01983657	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2012-01-31	2014-10-31	2015-10-31	-	-	2025-07-14
A Study on the Efficacy of Atezolizumab Combined with Chemotherapy	NCT06780826	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2024-08-28	2025-09-30	2026-09-30	-	-	2025-07-14
Construction and Evaluation of the Liquid Biopsy-based Early Diagnostic Model for Lung Cancer	NCT04156360	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2019-11-01	2021-06-01	2022-06-01	-	-	2025-07-14
Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung Disease	NCT05824988	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2023-04-14	2026-10-31	2027-10-31	-	-	2025-07-14
Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%	NCT03351842	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2017-09-01	2024-09-01	2025-09-01	-	-	2025-07-14
Comparison of Single Port and Two Ports Robotic Assisted Thoracic Surgery for Thymectomy	NCT05262582	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2022-05-10	2025-01-01	2026-01-01	-	-	2025-07-14
Clinical Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis	NCT02136992	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2011-12-31	2013-12-31	2014-12-31	-	-	2025-07-14
CX3CR1+T Cell Predict Immunotherapy Efficacy	NCT06054152	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2023-04-10	2025-06-20	2026-06-20	-	-	2025-07-14
Multicenter Observational Study of Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Rare Driver Gene Mutation	NCT04137718	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2019-10-25	2024-10-20	2025-10-20	-	-	2025-07-14
Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer	NCT04702009	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2021-01-20	2026-01-20	2027-01-20	-	-	2025-07-14
Therapy of Bronchoalveolar Lavage and Local Amikacin Injection in Patients With Acute Exacerbation of Bronchiectasis	NCT02509091	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2014-12-31	2019-06-30	2020-06-30	-	-	2025-07-14
The C-BRIDGE Study: China Bronchiectasis Research Involving Databases, Genomics, and Endotyping	NCT06900062	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2025-04-06	2029-01-31	2030-01-31	-	-	2025-07-14
Deep Learning Signature for Predicting Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung Cancer	NCT05925751	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2023-05-01	2023-10-31	2024-10-31	-	-	2025-07-14
a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung Cancer	NCT04790539	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2021-04-01	2022-12-31	2023-12-31	-	-	2025-07-14
A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB	NCT05493267	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2022-08-03	2027-08-03	2028-08-03	-	-	2025-07-14
Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma	NCT04713761	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2021-02-01	2025-05-31	2026-05-31	-	-	2025-07-14
Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients	NCT06987734	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2025-06-19	2028-08-31	2029-08-31	-	-	2025-07-14
Updated Severity and Prognosis Score of Pulmonary Alveolar Proteinosis	NCT04516577	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2020-01-01	2021-12-31	2022-12-31	-	-	2025-07-14
A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC	NCT06585644	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2024-10-01	2030-06-01	2031-06-01	-	-	2025-07-14
Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial	NCT06282536	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2024-03-31	2029-12-31	2030-12-31	-	-	2025-07-14
Transthoracic Needle Biopsy Using 3D Printed Navigational Template: A Phase I Feasibility Trial	NCT03325907	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2020-06-01	2020-09-03	2021-09-03	-	-	2025-07-14
Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study	NCT04762030	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2021-02-08	2025-12-30	2026-12-30	-	-	2025-07-14
Clinical Study of New Intensive Treatment Regimen for Severe Nontuberculous Mycobacterial Pulmonary Disease	NCT05494957	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2022-08-05	2025-08-05	2026-08-05	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance